An estimated 39,000 cases of cholangiocarcinoma (CC) were diagnosed in the United States in 2016.1 Of the patients with diagnoses of CC, two-thirds are unable to undergo surgical resection and require locoregional therapy.2,3 Given the ever-rising prevalence of this condition and the intimate involvement of the advanced endoscopist in the care of these patients, intraductal therapies have arisen, which may serve an important role in the care of CC.